BOYNTON BEACH, Fla., and MADRID, Spain, March 5, 2003 (PRIMEZONE) -- Jacobson Resonance Enterprises Inc., (OTCBB:JRSE) announces that its licensee BioRes Medical (Serrato Europe Sarl Company) has recently received the CE-MARK for it's new "Automated Treatment Delivery System," (ATDS360-18). This Magnetic Resonance Therapeutic Treatment (MRT) is the first one of its kind approved by the European Union.
The ATDS Automated Treatment Delivery System and the MRT for the 18-inch Jacobson Resonator consists of a unit that automatically controls the treatment of chronic pain. The ATDS and the MRT work together and is operated by a disposable computer chip card that contains the appropriate treatment protocol for each individual patient.
Harvey Grossman, President and COO of JRSE stated, "This system offers a number of cost saving and efficiency benefits since it requires a minimum of hospital staff intervention. The treatment session is totally automated which provides a very reliable and precise delivery of the treatment."
According to Alfonso Serrato, President and CEO of BioRes Medical, "At present time this new ATDS delivery system is operating in 8 hospitals in Spain, and, is projected that in the second quarter of 2003 the ATDS system will be operating in at least 20 hospitals in Spain. Furthermore, we project that in the second half of 2003 the ATDS system will be placed in additional countries in the European Union."
Mr. Grossman concluded, "We believe that revenues will increase proportionately as this system is accepted by the European Community. Also, JRSE's licensees are currently negotiating to distribute resonators in Central and South America, The Caribbean Basin, The Pacific Rim, Australia and New Zeeland."
In Canada, our licensee, Bio Resonance Technology, Inc, previously received licensing rights from Health Canada for the reduction of pain from arthritic conditions. Hundreds of patients have been successfully treated at their Winnipeg pain center.
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, food and beverage, pharmaceuticals, construction and the environment.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements.